期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
葡萄糖氧化酶和酵母硒对肉鸡非特异性免疫功能和抗氧化性能的影响 被引量:5
1
作者 刘娇 王昕陟 +3 位作者 孙丹彤 李忠秋 王媛 杨帆 《饲料研究》 CAS 北大核心 2020年第2期19-22,共4页
试验旨在研究葡萄糖氧化酶和酵母硒对肉鸡非特异性免疫功能和抗氧化性能的影响。分别在基础饲粮上设置2个酵母硒水平(0和0.2 mg/kg)和2个葡萄糖氧化酶水平(0和0.3 U/g),组成4种饲粮,随机分配给动物。试验期为26 d。结果表明:饲粮中添加... 试验旨在研究葡萄糖氧化酶和酵母硒对肉鸡非特异性免疫功能和抗氧化性能的影响。分别在基础饲粮上设置2个酵母硒水平(0和0.2 mg/kg)和2个葡萄糖氧化酶水平(0和0.3 U/g),组成4种饲粮,随机分配给动物。试验期为26 d。结果表明:饲粮中添加葡萄糖氧化酶和酵母硒均能提高肉鸡平均日增重,葡萄糖氧化酶和酵母硒对肉鸡生长性能没有互作效应(P>0.05)。葡萄糖氧化酶和酵母硒对免疫器官指数和溶菌酶含量无显著影响,且不存在互作效应(P>0.05)。葡萄糖氧化酶和酵母硒交互作用对40日龄补体C3含量有显著影响(P<0.05)。葡萄糖氧化酶具有提高28日龄和40日龄谷胱甘肽过氧化物酶(GSH-Px)含量的趋势(P=0.06和P=0.08)。酵母硒对GSH-Px含量无显著影响(P>0.05),且二者之间不存在互作关系(P>0.05)。本试验条件下,饲粮中添加葡萄糖氧化酶和酵母硒均能提高肉鸡平均日增重,但不存在互作关系。葡萄糖氧化酶可以提高早期肉鸡免疫器官指数,增强血清谷胱甘肽过氧化物酶活性。酵母硒和葡萄糖氧化酶对肉鸡血清补体C3含量有显著的互作效应。 展开更多
关键词 葡萄糖氧化酶 酵母硒 肉鸡 非特异性免疫功能 抗氧化性能
下载PDF
Attribution of Antioxidation of Quercetin in Vitro and Arbor Acre Broilers 被引量:1
2
作者 Wu Hao Liu Jia-yan +6 位作者 Zhou Shuai-shuai Ding Man-yi Fu Yu-xin Yang Qin-lin Maria Tabassum Chaudhry sun dan-tong Li Yao 《Journal of Northeast Agricultural University(English Edition)》 CAS 2022年第2期38-50,共13页
The antioxidant effects of quercetin were studied in vitro and in vivo.In vitro,vitamin C was used as a positive control to evaluate the antioxidant capacity of quercetin in three aspects:scavenging free radicals,prot... The antioxidant effects of quercetin were studied in vitro and in vivo.In vitro,vitamin C was used as a positive control to evaluate the antioxidant capacity of quercetin in three aspects:scavenging free radicals,protecting biological macromolecules and the total reducing power.In vivo,a total of 240 AA broilers(1-day age)with similar body weight were randomly divided into four groups with six replicates in each group,and 10 broilers in each replicate.The four groups were fed with corn-soybean basal diet supplemented with 0.00%,0.02%,0.04%and 0.06%quercetin to study its effects on antioxidant indexes of AA broilers,and to explore the optimal dose of quercetin as a dietary additive.The results showed that quercetin scavenged superoxide anion,hydroxyl radical and 1,1-diphenyl-2-picrylhydrazyl(DPPH)in vitro,the scavenging effects of quercetin on O_(2)-and•OH first increased and then decreased with the increase of the concentrations(P<0.01),and its maximum scavenging effect was observed at concentrations of 40 and 300 mg·L^(-1).The scavenging effects of quercetin on DPPH was increased constantly with increasing concentrations.The scavenging effect of quercetin on three free radicals was DPPH>•OH>O_(2)-.The inhibition of vitelline lipoprotein peroxidation by quercetin was increased with increasing concentrations(P<0.01)and the inhibitory effect was higher than that of vitamin C.The inhibition of red blood cell hemolysis by quercetin was increased with increasing concentrations at 0.05-1.25 mg·L^(-1)(P<0.01);however,the inhibition tended to decrease when the concentration was too high(31.25 mg·L^(-1)),and the inhibitory effect was higher than that of vitamin C.The inhibition of mitochondrial expansion by quercetin was increased with increasing concentrations,according to the degree of mitochondrial expansion at 60 min,the integrity of mitochondria in the experimental groups was significantly higher than that in the model group(P<0.01).The total reducing power of quercetin was increased with increasing concentrations(P<0.01);however,the total reducing power was less than that of vitamin C.In vivo,malondialdehyde(MDA)and nitric oxide(NO)were significantly decreased with increasing quercetin(P<0.01).Quercetin supplementation had no effect on the content of lipid peroxidation(LPO)in livers(P>0.05);however,superoxide dismutase(SOD)activity was significantly increased,whereas glutathione peroxidase(GSH-Px)and catalase(CAT)activities were significantly decreased in livers with increasing quercetin(P<0.05).These results suggested that quercetin exhibited strong antioxidant effects in vitro and in vivo. 展开更多
关键词 QUERCETIN antioxidant in vitro AA broilers
下载PDF
间变性淋巴瘤激酶-酪氨酸激酶抑制剂治疗非小细胞肺癌的临床应用及研究进展 被引量:4
3
作者 孙丹彤 侯和磊 张晓春 《中国新药杂志》 CAS CSCD 北大核心 2019年第2期164-172,共9页
ALK基因突变是目前临床上非小细胞肺癌(NSCLC)的个体化靶向治疗的重要靶点之一,ALK阳性NSCLC约占所有NSCLC 2%~7%。第1代ALK-TKIs药物crizotinib已经广泛应用于临床,对晚期NSCLC疗效肯定。但是,在应用crizotinib平均10. 9个月后,往往... ALK基因突变是目前临床上非小细胞肺癌(NSCLC)的个体化靶向治疗的重要靶点之一,ALK阳性NSCLC约占所有NSCLC 2%~7%。第1代ALK-TKIs药物crizotinib已经广泛应用于临床,对晚期NSCLC疗效肯定。但是,在应用crizotinib平均10. 9个月后,往往会出现耐药。同时,由于crizotinib的不良反应令部分患者不能耐受,使晚期NSCLC的治疗陷入窘境。此时,是否还有更为有效、广谱的新型ALKTKIs来替代crizotinib,是值得关注的。本文将以crizotinib为线索,总结ALK-TKIs在临床治疗NSCLC方面的研究进展。 展开更多
关键词 间变性淋巴瘤激酶 酪氨酸激酶抑制剂 CRIZOTINIB 非小细胞肺癌
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部